BPC-157 & TB-500
Select a filled cell to read the certificate.
BPC-157 & TB-500 Blend (10mg/10mg) — Research Peptide
The high-dose BPC-157 and TB-500 combination at 10mg/10mg per vial is designed for research protocols requiring elevated concentration ranges or extended experimental timelines. This format provides the same complementary dual-mechanism profile as the 5mg/5mg blend, with double the compound mass per vial for larger-scale or multi-arm experimental designs.
Research Applications
The 10mg/10mg format is particularly suited to research contexts where:
- Higher dose ranges need to be explored in dose-escalation studies
- Multiple experimental groups require identical batch sourcing
- Extended in vivo protocols (12+ week models) require consistent supply
- In vitro work requires high-concentration stock solutions
Compound Profiles
BPC-157 (10mg): Pentadecapeptide studied in tendon, ligament, muscle, gastrointestinal, and neurological research models. Primary mechanism: VEGFR2-Akt-eNOS angiogenic pathway and EGR1-mediated collagen gene expression.
TB-500/Tβ4 fragment (10mg): Actin-sequestering peptide fragment studied in wound healing, cardiac progenitor mobilisation, and skeletal muscle satellite cell research. Primary mechanism: G-actin sequestration enabling lamellipodia formation and directed cell migration.
Product Specifications
- Peptides: BPC-157 (10mg) + TB-500/Tβ4 fragment (10mg)
- Format: Co-lyophilised powder blend, bulk box of 10 vials
- Purity: ≥98% per component, Janoshik HPLC verified
- Testing: Full Janoshik COA available on request
- Storage: -20°C lyophilised. 24-month stability.
For laboratory research use only. Not for human therapeutic use.
